Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2011

View Archived Issues

AZD-4547 shows preclinical potential to treat solid tumors

TTAC-0001 displays antitumor efficacy in various models

Second-generation tumor metabolism inhibitor PENAO shows promise in vitro and in vivo

Antibody-drug conjugate BAY-94-9343 is active against mesothelin-expressing tumors

Novel inhibitors of human neutrophil elastase prepared

Nano Terra licenses three new products to Kadmon Pharma

Genetic markers of prostate cancer mortality identified in castration-resistant disease

AY-4 inhibits tumor growth in model of head and neck cancer

TransTech patents new compounds for Alzheimer's disease

Kuros Biosurgery regains rights to several products from Baxter

Vical reports promising phase I data on Vaxfectin-adjuvanted H1N1 pandemic flu vaccine

Merck & Co. presents new melanin-concentrating hormone MCH1 receptor antagonists

Eli Lilly and Medtronic form drug-device collaboration for Parkinson's disease

FDA approves additional indication for Lamictal XR

Novel PET tracers presented by University of Zagreb

Columbia Labs submits NDA to FDA for Prochieve to reduce risk of preterm birth

New antiprotozoal compounds reported

Dyax and Five Prime join to identify therapeutic antibodies against multiple targets

Primary endpoints met in phase II Vyvans trial in schizophrenia

Capstone Therapeutics reports final data from phase IIa AZX-100 trial

Adherex Technologies enrolls first patient in phase II eniluracil trial

OncoMed receives FDA clearance to advance anticancer candidate OMP-18R5 into phase I

FDA approves Zytiga in combination with prednisone for metastatic CRPC

Unigene completes enrollment in phase II study of oral parathyroid hormone for osteoporosis

Mirapex LA tablet approved in Japan for Parkinson's disease

Karo Bio and Alkem Laboratories enter collaboration and license agreement for eprotirome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...